Sleep Disorders

Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
Research/Studies Obstructive Sleep Apnea

Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings

Inspire Medical Systems, Inc. published Inspire V clinical outcomes data from its Singapore clinical study, as well as the Company’s limited market release in the United States, including single-site experience at two leading centers. These data will be presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical […]

TAP Sleep Care Secures Full Medicare Portfolio Coverage: Nylon flexTAP® Receives PDAC Approval under E0486
Obstructive Sleep Apnea AASM Dental Sleep Medicine

Nylon flexTAP Becomes the First FDA-cleared 3D-Printed Midline Oral Appliance for Sleep Apnea

Airway Management proudly announces a historic milestone with the FDA clearance of Nylon flexTAP®, the world’s first digitally printed single-point midline oral appliance device for sleep apnea. This revolutionary device redefines patient care by combining cutting-edge patented Vertex Technology® with unparalleled comfort and efficacy, now FDA cleared for mild to moderate obstructive […]

Home Sleep Testing (HST) Obstructive Sleep Apnea

Expert Insights: Dormotech Talks with Yale’s Dr. Meir Kryger on the Changing Landscape of Sleep Testing

Dormotech shares the release of a compelling expert highlight interview featuring Dr. Meir Kryger, Emeritus Professor at Yale School of Medicine. In this exclusive discussion, Dr. Kryger, a revered figure in the sleep industry who has been involved in sleep medicine since 1974, shares his unique perspective on the transformative […]

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Sleep Pharmaceuticals Industry News Narcolepsy

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore.   Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) […]

3 Powerful Takeaways from the 2025 WUN National Summit
WUN Advocacy/Awareness Narcolepsy

The Power of WUN

Attendees traveled from near and far to join us in person and online for the 2025 Wake Up Narcolepsy National Summit in Raleigh-Durham, N.C. Hosted in a different city each year, the summit provides a place where industry professionals, clinicians, individuals with narcolepsy, and family members can come together and […]